Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.

[1]  B. Ryffel,et al.  Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[2]  H. Collard,et al.  Epidemiology of idiopathic pulmonary fibrosis , 2013, Clinical epidemiology.

[3]  I. Wiklund,et al.  Content Validity of CASA-Q Cough Domains and UCSD-SOBQ for Use in Patients with Idiopathic Pulmonary Fibrosis , 2013, Global journal of health science.

[4]  H. Collard,et al.  Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials , 2013, Respiratory Research.

[5]  K. Flaherty,et al.  Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. , 2013, Current opinion in pharmacology.

[6]  H. Collard,et al.  Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. , 2012, American journal of respiratory and critical care medicine.

[7]  R. D. du Bois,et al.  Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. , 2012, American journal of respiratory and critical care medicine.

[8]  K. Anstrom,et al.  The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. , 2012, Respiratory medicine.

[9]  D. Fairclough,et al.  Patient-reported outcomes in idiopathic pulmonary fibrosis research. , 2012, Chest.

[10]  G. Raghu,et al.  Treatment Of IPF With The Tyrosine Kinase Inhibitor BIBF 1120: Patient-Reported Outcomes In The TOMORROW Trial , 2012, ATS 2012.

[11]  Joyce S Lee,et al.  Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis , 2012, Thorax.

[12]  S. Sahn,et al.  Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.

[13]  Luca Richeldi,et al.  Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. , 2011, The New England journal of medicine.

[14]  V. Hirsh.  Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. , 2011, Current Oncology.

[15]  Mellar P. Davis,et al.  Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. , 2011, The oncologist.

[16]  R. Hubbard,et al.  The rising incidence of idiopathic pulmonary fibrosis in the UK , 2011, Thorax.

[17]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[18]  H. Collard,et al.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[19]  W. Coward,et al.  The pathogenesis of idiopathic pulmonary fibrosis , 2010, Therapeutic advances in respiratory disease.

[20]  P. Jones,et al.  Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire , 2010, Thorax.

[21]  G. Raghu,et al.  The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. , 2010, Respiratory medicine.

[22]  A. Nicholson,et al.  Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[23]  H. Magnussen,et al.  Development and validation of a cough and sputum assessment questionnaire. , 2008, Respiratory Medicine.

[24]  W. Sommergruber,et al.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.

[25]  G J Roth,et al.  Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis , 2007, European Respiratory Journal.

[26]  H. Collard,et al.  Acute exacerbations of idiopathic pulmonary fibrosis. , 2007, American journal of respiratory and critical care medicine.

[27]  G. Oster,et al.  Incidence and prevalence of idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.

[28]  A. Stewart,et al.  Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives , 2005, Health and quality of life outcomes.

[29]  J. Hankinson,et al.  Standardisation of the single-breath determination of carbon monoxide uptake in the lung , 2005, European Respiratory Journal.

[30]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[31]  M. Gould,et al.  Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review , 2005, Thorax.

[32]  G. Raghu,et al.  Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. , 2005, Chest.

[33]  F. Martinez,et al.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[34]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[35]  H. Collard,et al.  Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.

[36]  R. Kaplan,et al.  Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. , 1998, Chest.

[37]  J. Roca,et al.  Standardization of the measurement of transfer factor (diffusing capacity) , 1993, European Respiratory Journal.

[38]  J. Roca,et al.  Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[39]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[40]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.